Results 91 to 100 of about 13,407 (237)

Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy [PDF]

open access: yes, 2016
No abstract ...
Arrigo   +48 more
core   +4 more sources

Post-COVID Tachycardia Syndrome: Could It Be Myocarditis? A Case Report of a Patient Treated with Ivabradine [PDF]

open access: bronze, 2023
Davyson Gerhardt de Souza   +3 more
openalex   +1 more source

Current Trends in Duchenne Muscular Dystrophy Research and Therapy: 3D Cardiac Modelling

open access: yesJournal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 1, February 2026.
ABSTRACT Duchenne muscular dystrophy (DMD), caused by dystrophin deficiency, presents a multifaceted challenge that affects both skeletal muscle function and cardiomyocyte homeostasis, causing progressive degeneration and life‐threatening cardiac complications by adolescence.
Marta Przymuszała   +3 more
wiley   +1 more source

Evaluating the applicability of ivabradine in acute heart failure [PDF]

open access: gold, 2023
Tzu‐Hsien Tsai   +7 more
openalex   +1 more source

Cardiac Resynchronization Therapy: Reconsidering Its Essence as a Treatment for Electrical Dyssynchrony in Heart Failure

open access: yesJournal of Arrhythmia, Volume 42, Issue 1, February 2026.
Flow of cardiac resynchronization therapy (CRT) in heart failure management. Heart failure (HF) patients with electrical dyssynchrony are first identified through screening. If electrical dyssynchrony contributes to HF deterioration, CRT is initiated to improve electrical synchrony.
Michio Ogano   +4 more
wiley   +1 more source

Concomitant Administration of Different Doses of Simvastatin with Ivabradine Influence on PAI-1 and Heart Rate in Normo- and Hypercholesterolaemic Rats

open access: yesThe Scientific World Journal, 2012
Ivabradine is a novel heart rate lowering agent that inhibits If ionic current in the sinus node and demonstrates antiischaemic and antianginal activity.
Jacek Owczarek   +2 more
doaj   +1 more source

Population Physiologically‐Based Pharmacokinetic Modeling to Determine Ontogeny: A Quantitative Clinical Pharmacology Example in Pediatric Rare Disease

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Pediatric physiologically‐based pharmacokinetic (PBPK) modelling plays an increasing role in selecting doses in children and addressing clinical pharmacology questions. Ethical concerns often limit clinical pharmacology studies that have no direct therapeutic benefit in children, highlighting the value of PBPK model predictions.
Yumi Cleary   +4 more
wiley   +1 more source

Acute Effects of Ivabradine on Dynamic Obstruction of the Left Ventricular Outflow Tract in Cats with Preclinical Hypertrophic Cardiomyopathy

open access: yesJournal of Veterinary Internal Medicine, 2014
Background Ivabradine is a negative chronotropic drug with minimal effects on central hemodynamics. Its effect on dynamic obstruction of the left ventricular outflow tract (LVOT) in cats with hypertrophic cardiomyopathy (HCM) remains unknown.
K.A. Blass   +4 more
doaj   +1 more source

Ivabradine in acute heart failure: Effects on heart rate and hemodynamic parameters in a randomized and controlled swine trial

open access: yesCardiology Journal, 2020
BACKGROUND: Acute heart failure patients could benefit from heart rate reduction, as myocardial consumption and oxidative stress are related to tachycardia. Ivabradine could have a clinical role attenuating catecholamine-induced tachycardia.
Marina Pascual Izco   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy